Robert E. Gagnon, Chief Financial Officer of Opus Genetics, Inc. (NASDAQ:IRD), filed a Form 4 on September 8, 2026, disclosing the sale of 28,000 shares of common stock on September 3, 2026.

Key Highlights

  • Reporting Person: Robert E. Gagnon, Chief Financial Officer of Opus Genetics, Inc.
  • Transaction: 28,000 shares of common stock disposed of (transaction code S) on September 3, 2026.
  • Weighted Average Price: $4.5433 per share, with individual sales ranging from $4.29 to $4.79, inclusive.
  • Remaining Ownership: 556,375 shares of common stock held directly following the transaction.
  • Dual Purpose Sale: A portion of shares were sold automatically to satisfy tax withholding on vested restricted stock units; the remainder were sold under a Rule 10b5-1 trading plan adopted April 30, 2026.

Details of Gagnon's Share Disposition at Opus Genetics

According to the filing, Robert E. Gagnon disposed of 28,000 shares of Opus Genetics common stock on September 3, 2026, at a weighted average price of $4.5433 per share. The shares were sold across multiple transactions at prices ranging from $4.29 to $4.79, inclusive. The filing notes that Gagnon undertakes to provide full information regarding the number of shares sold at each separate price within that range upon request from the issuer, any securityholder, or SEC staff.

The filing discloses that the sale had two components. A portion of the shares were sold automatically on Gagnon's behalf, as required by Opus Genetics, to cover tax withholding obligations arising from the vesting and settlement of restricted stock units. The remaining shares were sold pursuant to a Rule 10b5-1 trading plan that Gagnon adopted on April 30, 2026. The filing describes this plan as "a pre-arranged written trading plan pursuant to which shares of the Issuer's common stock are sold automatically based on a predetermined formula that was established by the Reporting Person at a time when the Reporting Person was not aware of any material nonpublic information about the Issuer."

Following the reported transaction, Gagnon directly holds 556,375 shares of Opus Genetics common stock, according to the filing. The Form 4 was signed by Amy Rabourn by Power of Attorney and filed on September 8, 2026.

What Was Disclosed

The filing reports a single open-market sale of 28,000 common shares by Opus Genetics' CFO on September 3, 2026, executed partly for tax withholding on RSU vesting and partly under a pre-established Rule 10b5-1 plan, leaving 556,375 shares directly owned.